by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Naveh Pharma LTD/Bigdam Inc. Warning Letter Details

Warning Letter

Naveh Pharma LTD/Bigdam Inc.

Recipient Name Tal Bornstein, CEO, Recipient Title Roei Farhi, CEO, 19, Yad Kharutsim St. Netanya, Sharon area Israel

Issue DateMay 04, 2026

FEI Number3027300316

Violations2

CountryN/A

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug

Naveh Pharma LTD/Bigdam Inc. FDA Warning Letter, May 4, 2026